Three iadademstat abstracts have been accepted for presentation at the upcoming ASH-2025 Annual MeetingPreliminary data from the ongoing Phase Ib trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a 100% overall response rateUpdated preliminary data from the ongoing Phase Ib FRIDA trial evaluating iadademstat in combination with gilteritinib in FLT3-mutated relapsed/refractory AML showed a 67% response rate in the expanded dose, superior to both histori ...